| 1 |
Buchan AM, Warren D, Burnstein R. Transplantation of cultured human neuronal cells for patients with stroke[J]. Neurology, 2001, 56(6):821-822.
|
| 2 |
黄红云，王洪美，修波等.临床研究嗅鞘细胞移植治疗脊髓损伤临床试验的初步报告[J].海军总医院学报，2002，15(1):18-21.
|
| 3 |
Huang H, Chen L, Wang H, et al. Influence of patients' age on functional recovery after transplantation of olfactory ensheathing cells into injured spinal cord injury[J]. Chin Med J (Engl), 2003,116(10):1488-1491.
|
| 4 |
Rabinovich SS, Seledtsov VI, Poveschenko OV, et al. Transplantation treatment of spinal cord injury patients[J]. Biomed Pharmacother, 2003, 57(9):428-433.
|
| 5 |
Huang H, Xi H, Chen L, et al. Long-term outcome of olfactory ensheathing cell therapy for patients with complete chronic spinal cord injury[J]. Cell Transplant, 2012, Suppl 1:S23-31.
|
| 6 |
Huang H, Chen Lin, Mao G, et al. Clinical neurorestorative cell therapies: developmental process, current state, and future prospective[J]. J Neurorestoratology, 2020, 8(2):61-82.
|
| 7 |
Kondziolka D, Steinberg GK, Wechsler L, et al. Neurotransplantation for patients with subcortical motor stroke:a phase 2 randomized trial[J]. J Neurosurg, 2005, 103(1):38-45.
|
| 8 |
Prasad K, Sharma A, Garg A, et al. Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke:a multicentric, randomized trial[J]. Stroke, 2014, 45(12):3618-3624.
|
| 9 |
Savitz SI, Yavagal D, Rappard G, et al. A phase 2 randomized, sham-controlled trial of internal carotid artery infusion of autologous bone marrow derived ALD-401 cells in patients with recent stable ischemic stroke （RECOVER-Stroke）[J]. Circulation, 2019, 139(2):192-205.
|
| 10 |
Hess DC, Wechsler LR, Clark WM, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke （MASTERS）:a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Neurol, 2017, 16(5):360-368.
|
| 11 |
Fang J, Guo Y, Tan S, et al. Autologous endothelial progenitor cells transplantation for acute ischemic stroke:A 4-year follow-up study[J]. Stem Cells Transl Med, 2019, 8(1):14-21.
|
| 12 |
SanBio Co. Ltd. SanBio and Sumitomo Dainippon Pharma announce topline results from a phase 2b study in the U.S. Evaluating SB623, a regenerative cell medicine for the treatment of patients with chronic stroke[EB/OL]. (2019-01-29).
URL
|
| 13 |
Rah WJ, Lee YH, Moon JH, et al. Neuroregenerative potential of intravenous G-CSF and autologous peripheral blood stem cells in children with cerebral palsy:a randomized, double-blind, cross-over study[J]. J Transl Med, 2017,15(1):16.
|
| 14 |
Sun JM, Song AW, Case LE, et al. Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy:a randomized, placebo-controlled trial[J]. Stem Cells Transl Med, 2017, 6(12):2071-2078.
|
| 15 |
Levi AD, Anderson KD, Okonkwo DO, et al. Clinical outcomes from a multi-center study of human neural stem cell transplantation in chronic cervical spinal cord injury[J]. J Neurotrauma, 2019, 36(6):891-902.
|
| 16 |
Oh SK, Choi KH, Yoo JY, et al. A phaseⅢ clinical trial showing limited efficacy of autologous mesenchymal stem cell therapy for spinal cord injury[J]. Neurosurgery, 2016, 78(3):436-447.
|
| 17 |
Lublin FD, Bowen JD, Huddlestone J, et al. Human placenta-derived cells （PDA-001） for the treatment of adults with multiple sclerosis:a randomized, placebo-controlled, multiple-dose study[J]. Mult Scler Relat Disord, 2014, 3(6):696-704.
|
| 18 |
Berry JD, Cudkowicz ME, Windebank AJ, et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS:Safety, clinical, and biomarker results[J]. Neurology, 2019, 93(24):e2294-e2305.
|
| 19 |
Jaillard A, Hommel M, Moisan A, etal. Autologous mesenchymal stem cells improve motor recovery in subacute ischemic stroke:a randomized clinical trial[J]. Transl Stroke Res, 2020, 11(5):910-923.
|
| 20 |
Law ZK, Tan HJ, Chin SP, et al. The effects of intravenous infusion of autologous mesenchymal stromal cells in patients with subacute middle cerebral artery infarct:a phase 2 randomized controlled trial on safety, tolerability and efficacy[J]. Cytotherapy, 2021, 23(9):833-840.
|
| 21 |
Chung JW, Chang WH, Bang OY, et al. Efficacy and safety of intravenous mesenchymal stem cells for ischemic stroke[J]. Neurology, 2021, 96(7):e1012-e1023.
|
| 22 |
Kawabori M, Weintraub AH, Imai H, et al. Cell therapy for chronic TBI:interim analysis of the randomized controlled STEMTRA trial[J]. Neurology, 2021, 96(8):e1202-e1214
|
| 23 |
Wang Y, Guo X, Liu Y, et al. A pilot study of clinical cell therapy for patients with vascular dementia[J]. J Neurorestoratology, 2021, 9:137-150.
|
| 24 |
Guo X, Wang Y, Li Y, et al. A pilot study of clinical cell therapies in Alzheimer's disease[J]. J Neurorestoratology, 2021, 9:269-284.
|
| 25 |
Huang H, Mao G, Chen L, et al. Clinical neurorestorative cell therapies for stroke[J]. Prog Brain Res, 2021, 265:231-247.
|
| 26 |
Syková E, Homola A, Mazanec R, et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury[J]. Cell Transplant, 2006, 15(8-9):675-687.
|
| 27 |
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotentmesenchymal stromal cells. The International Society for Cellular Therapy position statement[J]. Cytotherapy, 2006, 8(4):315-317.
|
| 28 |
Galipeau J, Krampera M, Barrett J, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials[J]. Cytotherapy, 2016, 18(2):151-159.
|
| 29 |
黄红云，毛更生，陈琳. 神经修复临床细胞治疗现状与展望[J]. 中华细胞与干细胞杂志（电子版）, 2017,7(3):162-167.
|
| 30 |
Saberi H, Firouzi M, Habibi Z, et al. Safety of intramedullary Schwann cell transplantation for postrehabilitation spinal cord injuries:2-year follow-up of 33 cases[J]. J Neurosurg Spine, 2011,15(5):515-525.
|
| 31 |
Zhou XH, Ning GZ, Feng SQ, et al. Transplantation of autologous activated Schwann cells in the treatment of spinal cord injury:six cases, more than five years of follow-up[J]. Cell Transplant, 2012, 21 Suppl 1:S39-47.
|
| 32 |
Glass JD, Boulis NM, Johe K, et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis:results of a phase I trial in 12 patients[J]. Stem Cells, 2012, 30(6):1144-1151.
|
| 33 |
Riley J, Glass J, Feldman EL, et al. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis:a phase I trial, cervical microinjection, and final surgical safety outcomes[J]. Neurosurgery, 2014, 74(1):77-87.
|
| 34 |
Feldman EL, Boulis NM, Hur J, et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis:phase 1 trial outcomes[J]. Ann Neurol, 2014, 75(3):363-373.
|
| 35 |
Glass JD, Hertzberg VS, Boulis NM, et al. Transplantation of spinal cord-derived neural stem cells for ALS:Analysis of phase 1 and 2 trials[J]. Neurology, 2016,87(4):392-400.
|
| 36 |
Goutman SA, Brown MB, Glass JD, et al. Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS[J]. Ann Clin Transl Neurol, 2018, 5(6):730-740.
|
| 37 |
Ren WQ, Yin F, Zhang JN, et al. Neural stem cell transplantation for the treatment of primary torsion dystonia:a case report[J]. Exp Ther Med, 2016, 12(2):661-666.
|
| 38 |
Liu Y, Chen SJ, Li SY, et al. Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients[J]. Stem Cell Res Ther, 2017, 8(1):209.
|
| 39 |
Rabinovich SS, Seledtsov VI, Banul NV, et al. Cell therapy of brain stroke[J]. BullExpBiol Med, 2005, 139(1):126-128.
|
| 41 |
Seledtsov VI, Kafanova MY, Rabinovich SS, et al. Cell therapy of cerebral palsy[J]. Bull Exp Biol Med, 2005, 139(4):499-503.
|
| 42 |
Seledtsov VI, Rabinovich SS, Parlyuk OV, et al. Cell transplantation therapy in re-animating severely head-injured patients[J]. Biomed Pharmacother, 2005, 59(7):415-420.
|
| 43 |
Seledtsov VI, Rabinovich SS, Kashchenko EA, et al. Immunological and clinical aspects of cell therapy in the treatment of aftereffects of craniocerebral injury[J]. Bull Exp Biol Med, 2006, 141(1):121-123.
|
| 44 |
Seledtsov VI, Rabinovich SS, Parlyuk OV, et al. Cell therapy of comatose states[J]. Bull Exp Biol Med,2006,142(1):129-132.
|
| 45 |
Yang XF, Xu YF, Zhang YB, et al. Functional improvement of patients with progressive muscular dystrophy by bone marrow and umbilical cord blood mesenchymal stem cell transplantations[J]. Zhonghua Yi Xue Za Zhi,2009,89(36):2552-2556.
|
| 46 |
Lv YT, Zhang Y, Liu M, et al. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism[J]. J Transl Med, 2013, 11:196. doi: 10.1186/1479-5876-11-196. |
| 47 |
Yazdani SO, Hafizi M, Zali AR, et al. Safety and possible outcome assessment of autologous Schwann cell and bone marrow mesenchymal stromal cell co-transplantation for treatment of patients with chronic spinal cord injury[J]. Cytotherapy,2013,15(7):782-791.
|
| 48 |
Oraee-Yazdani S, Hafizi M, Atashi A, et al. Co-transplantation of autologous bone marrow mesenchymal stem cells and Schwann cells through cerebral spinal fluid for the treatment of patients with chronic spinal cord injury:safety and possible outcome[J]. Spinal Cord, 2016,54(2):102-109.
|
| 49 |
Oraee-Yazdani S, Akhlaghpasand M, Golmohammadi M, et al. Combining cell therapy with human autologous Schwann cell and bone marrow-derived mesenchymal stem cell in patients with subacute complete spinal cord injury:safety considerations and possible outcomes[J]. Stem Cell Res Ther, 2021, 12(1):445. doi: 10.1186/s13287-021-02515-2. |
| 50 |
Zamani H, Soufizomorrod M, Oraee-Yazdani S, et al. Safety and feasibility of autologous olfactory ensheathing cell and bone marrow mesenchymal stem cell co-transplantation in chronic human spinal cord injury:a clinical trial[J]. Spinal Cord,2022,60(1):63-70.
|
| 51 |
Chen L, Xi H, Huang H, et al. Multiple cell transplantation based on an intraparenchymal approach for patients with chronic phase stroke[J]. Cell Transplant, 2013, Suppl 1:S83-91.
|
| 52 |
Xi H, Chen L, Huang H, et al. Preliminary report of multiple cell therapy for patients with multiple system atrophy[J]. Cell Transplant, 2013, Suppl 1:S93-99.
|
| 53 |
Chen L, Huang H, Xi H, et al. A prospective randomized double-blind clinical trial using a combination of olfactory ensheathing cells and Schwann cells for the treatment of chronic complete spinal cord injuries[J]. Cell Transplant, 2014, Suppl 1:S35-44.
|
| 54 |
Liu XB, Fu XJ, Dai GH, et al. Comparative analysis of curative effect of bone marrow mesenchymalstem cell and bone marrow mononuclear cell transplantation for spastic cerebral palsy[J]. J Transl Med, 2017, 15(1):48. doi: 10.1186/s12967-017-1149-0. |
| 55 |
Moviglia GA, Moviglia Brandolino MT, Couto D, et al. Local immunomodulation and muscle progenitor cells induce recovery in atrophied muscles in spinal cord injury patients[J]. J Neurorestoratology, 2018, 6(1):136-145.
|
| 56 |
van Horne CG, Quintero JE, Slevin JT, et al. Peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson's disease during deep brain stimulation surgery:1-year follow-upstudy of safety, feasibility, and clinical outcome[J]. J Neurosurg, 2018, 129(6):1550-1561.
|
| 57 |
Bryukhovetskiy . Tissue Engineering of spinal cord injury in Neurorestoratology[M]. Huang H, Raisman G, Sanberg PR, Sharma H, Chen L, eds. Vol 2. New York: Nova Biomedical, 2015:45-46
|
| 58 |
Xiao Z, Tang F, Tang J, et al. One-year clinical study of NeuroRegen scaffold implantation following scar resection in complete chronic spinal cord injury patients[J]. Sci China Life Sci, 2016, 59(7):647-655.
|
| 59 |
Zhao Y, Tang F, Xiao Z, et al. Clinical Study of NeuroRegen scaffold combined with human mesenchymal stem cells for the repair of chronic complete spinal cord injury[J]. Cell Transplant, 2017, 26(5):891-900.
|
| 60 |
Xiao Z, Tang F, Zhao Y, et al. Significant improvement of acute complete spinal cord injury patients diagnosed by a combined criteria implanted with NeuroRegen scaffolds and mesenchymal stem cells[J]. Cell Transplant, 2018, 27(6):907-915.
|
| 61 |
Tang F, Tang J, Zhao Y, et al. Long-term clinical observation of patients with acute and chronic complete spinal cord injury after transplantation of NeuroRegen scaffold[J]. Sci China Life Sci, 2021, 16. doi: 10.1007/s11427-021-1985-5. |
| 62 |
Murillo N, Kumru H, Opisso E, et al. Recovery of assisted overground stepping in a patient with chronic motor complete spinal cord injury:a case report[J]. NeuroRehabilitation, 2012, 31(4):401-407.
|
| 63 |
Donati AR, Shokur S, Morya E, et al. Long-term training with a brain-machine interface-based gait protocol induces partial neurological recovery in paraplegic patients[J]. Sci Rep, 2016, 6:30383. doi: 10.1038/srep30383. |
| 64 |
Angeli CA, Boakye M, Morton RA, et al. Recovery of over-ground walking after chronic motor complete spinal cord injury[J]. N Engl J Med, 2018, 379(13):1244-1250.
|
| 65 |
Gill ML, Grahn PJ, Calvert JS, et al. Neuromodulation of lumbosacral spinal networks enables independent stepping after complete paraplegia[J]. Nat Med, 2018, 24(11):1677-1682.
|
| 66 |
Herrity AN, Williams CS, Angeli CA, et al. Lumbosacral spinal cord epidural stimulation improves voiding function after human spinal cord injury[J]. Sci Rep, 2018, 8(1):8688. doi: 10.1038/s41598-018-26602-2. |
| 67 |
Terson de Paleville DGL, Harkema SJ, Angeli CA. Epidural stimulation with locomotor training improves body composition in individuals with cervical or upper thoracic motor complete spinal cord injury:A series of case studies[J]. J Spinal Cord Med, 2019, 42(1):32-38.
|
| 68 |
Wagner FB, Mignardot JB, Le Goff-Mignardot CG, et al. Targeted neurotechnology restores walking in humans with spinal cord injury[J]. Nature, 2018, 563(7723):65-71.
|
| 69 |
Harkema SJ, Wang S, Angeli CA, et al. Normalization of blood pressure with spinal cord epidural stimulation after severe spinal cord injury[J]. Front Hum Neurosci, 2018, 12:83. doi: 10.3389/fnhum.2018.00083. |
| 70 |
Aslan SC, Legg Ditterline BE, Park MC, et al. Epidural spinal cord stimulation of lumbosacral networks modulates arterial blood pressure in individuals with spinal cord injury-induced cardiovascular deficits[J]. Front Physiol, 2018, 9:565. doi: 10.3389/fphys.2018.00565. |
| 71 |
Peña Pino I, Hoover C, Venkatesh S, et al. Long-term spinal cord stimulation after chronic complete spinal cord injury enables volitional movement in the absence of stimulation[J]. Front SystNeurosci, 2020, 14:35. doi: 10.3389/fnsys.2020.00035. |
| 72 |
Huang HY, Young W, Skaper S, et al. Clinical neurorestorative therapeutic guidelines for spinal cord injury (IANR/CANR version 2019)[J]. J OrthopTranslat, 2019, 20:14-24.
|
| 73 |
Guo X, Feng Y, Sun T, et al. Clinical guidelines for neurorestorative therapies in spinal cord injury(2021 China version)[J]. J Neurorestoratology, 2021, 9(1):31-49.
|
| 74 |
Fassas A, Anagnostopoulos A, Kazis A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiplesclerosis:first results of a pilot study[J]. Bone Marrow Transplant, 1997, 20(8):631-638.
|
| 75 |
Fassas A, Anagnostopoulos A, Kazis A, etal. Autologous stem cell transplantation in progressive multiple sclerosis--an interim analysis of efficacy[J]. J ClinImmunol, 2000, 20(1):24-30.
|
| 76 |
Fassas A, Kimiskidis VK, Sakellari I, et al. Long-term results of stem cell transplantation for MS:a single-center experience[J]. Neurology, 2011, 76(12):1066-1070.
|
| 77 |
Saccardi R, Freedman MS, Sormani MP, et al. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis:a position paper[J]. MultScler, 2012, 18(6):825-834.
|
| 78 |
Moore JJ, Massey JC, Ford CD, et al. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis[J]. J Neurol Neurosurg Psychiatry, 2019, 90(5):514-521.
|
| 79 |
Scott CT, Magnus D. Wrongful termination:lessons from the Geron clinical trial[J]. Stem Cells Transl Med, 2014, 3(12):1398-1401.
|
| 80 |
Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy:follow-up of two open-label phase 1/2 studies[J]. Lancet, 2015, 385(9967):509-516.
|
| 81 |
da Cruz L, Fynes K, Georgiadis O, et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration[J]. Nat Biotechnol, 2018, 36(4):328-337.
|
| 82 |
Kashani AH, Lebkowski JS, Rahhal FM, et al. A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration[J]. SciTransl Med, 2018, 10(435):eaao4097. doi: 10.1126/scitranslmed.aao4097. |
| 83 |
Kashani AH, Uang J, Mert M, et al. Surgical method for implantation of a biosynthetic retinal pigment epithelium monolayer for geographic atrophy: experience from a phase 1/2a study[J]. Ophthalmol Retina, 2020, 4(3):264-273.
|
| 84 |
Mandai M, Watanabe A, Kurimoto Y, et al. Autologous induced stem-cell-derived retinal cells for macular degeneration[J]. N Engl J Med, 2017, 376(11):1038-1046.
|
| 85 |
Takagi S, Mandai M, Gocho K, et al. Evaluation of transplanted autologous induced pluripotent stem cell-derived retinal pigment epithelium in exudative age-related macular degeneration[J]. Ophthalmol Retina, 2019, 3(10):850-859.
|
| 86 |
Schweitzer JS, Song B, Herrington TM, et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson's disease[J]. N Engl J Med, 2020, 382(20):1926-1932.
|
| 87 |
Chen G, Wang Y, Xu Z, et al. Neural stem cell-like cells derived from autologous bone mesenchymal stem cells for the treatment of patients with cerebral palsy[J]. J Transl Med, 2013, 11:21.doi: 10.1186/1479-5876-11-21. |
| 88 |
Nafissi S, Kazemi H, Tiraihi T, et al. Intraspinal delivery of bone marrow stromal cell-derived neural stem cells in patients with amyotrophic lateral sclerosis:A safety and feasibility study[J]. J Neurol Sci, 2016, 362:174-181.
|
| 89 |
Steinberg GK, Kondziolka D, Wechsler LR, et al. Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke:a phase 1/2a study[J]. Stroke, 2016, 47(7):1817-1824.
|
| 90 |
Steinberg GK, Kondziolka D, Wechsler LR, et al. Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623):a phase 1/2a study[J]. J Neurosurg, 2018, 1-11.
|
| 91 |
Wang Z, Luo Y, Chen L, et al. Safety of neural stem cell transplantation in patients with severe traumatic brain injury[J]. Exp Ther Med, 2017, 13(6):3613-3618.
|
| 92 |
Gupta N, Henry RG, Kang SM, et al. Long-term safety, immunologic response, and imaging outcomes following neural stem cell transplantation for Pelizaeus-Merzbacher disease[J].Stem Cell Reports, 2019, 13(2):254-261.
|
| 93 |
Nittala MG, Uji A, Velaga SB, et al. Effect of human central nervous system stem cell subretinal transplantation on progression of geographic atrophy secondary to nonneovascular age-related macular degeneration[J]. Ophthalmol Retina, 2021, 5(1):32-40.
|
| 94 |
Levi AD, Okonkwo DO, Park P, et al. Emerging safety of intramedullary transplantation of human neural stem cells in chronic cervical and thoracic spinal cord injury[J]. Neurosurgery, 2018, 82(4):562-575.
|
| 95 |
Kalladka D, Sinden J, Pollock K, et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES):a phase 1, first-in-man study[J]. Lancet, 2016, 388(10046):787-796.
|
| 96 |
Muir KW, Bulters D, Willmot M, et al. Intracerebral implantation of human neural stem cells and motor recovery after stroke:multicentre prospective single-arm study (PISCES-2)[J]. J Neurol Neurosurg Psychiatry, 2020, 91(4):396-401.
|
| 97 |
Zhang GZ, Li Y, Reuss JL, et al. Stable intracerebral transplantation of neural stem cells for the treatment of paralysis due to ischemic stroke[J]. Stem Cells Transl Med, 2019, 8(10):999-1007.
|
| 98 |
Martínez HR, Molina-Lopez JF, González-Garza MT, et al. Stem cell transplantation in amyotrophic lateral sclerosis patients:methodological approach, safety, and feasibility[J]. Cell Transplant, 2012, 21(9):1899-1907.
|
| 99 |
Zali A, Arab L, Ashrafi F, et al. Intrathecal injection of CD133-positive enriched bone marrow progenitor cells in children with cerebral palsy:feasibility and safety[J]. Cytotherapy, 2015,17(2):232-241.
|
| 100 |
Moviglia GA, Varela G, Brizuela JA, et al. Case report on the clinical results of a combined cellular therapy for chronic spinal cord injured patients[J]. Spinal Cord, 2009, 47(6):499-503.
|
| 101 |
Moviglia GA, Moviglia-Brandolino MT, Varela GS, et al. Feasibility, safety, and preliminary proof of principles of autologous neural stem cell treatment combined with T-cell vaccination for ALS patients[J]. Cell Transplant, 2012, Suppl 1:S57-63.
|
| 102 |
Qiao LY, Huang FJ, Zhao M, et al. A two-year follow-up study of co-transplantation with neural stem/precursor cells and mesenchymal stromal cells in ischemic stroke patients[J]. Cell Transplant, 2014, Suppl 1:S65-S72.
|
| 103 |
Thakkar UG, Vanikar AV, Trivedi HL, et al. Infusion of autologous adipose tissue derived neuronal differentiated mesenchymal stem cells and hematopoietic stem cells in post-traumatic paraplegia offers a viable therapeutic approach[J]. Adv Biomed Res, 2016, 5:51. doi: 10.4103/2277-9175.178792. |
| 104 |
Ammar AS, Osman Y, Hendam AT, et al. A method for reconstruction of severely damaged spinal cord using autologous hematopoietic stem cells and platelet-rich protein as a biological scaffold[J]. Asian J Neurosurg, 2017, 12(4):681-690.
|
| 105 |
Wang YL, Guo XL, Liu J, et al. Olfactory ensheathing cells in chronic ischemic stroke:A phase 2 double-blind, randomized, controlled trial[J]. J Neurorestoratology, 2020, 8(3):182-193.
|
| 106 |
Min K, Suh MR, Cho KH, et al. Potentiation of cord blood cell therapy with erythropoietin for children with CP:a 2 × 2 factorial randomized placebo-controlled trial[J]. Stem Cell Res Ther, 2020, 11(1):509. doi: 10.1186/s13287-020-02020-y. |
| 107 |
Petrou P, Kassis I, Levin N, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis[J]. Brain, 2020, 143(12):3574-3588.
|
| 108 |
Petrou P, Kassis I, Ginzberg A, et al. Long-term clinical and immunological effects of repeated mesenchymal stem cell injections in patients with progressive forms of multiple sclerosis[J]. Front Neurol, 2021, 12:639315. doi: 10.3389/fneur.2021.639315. |
| 109 |
Xiang S, Gao W, Peng H, et al. Standards of clinical-grade mesenchymal stromal cell preparation and quality control (2020 China Version)[J]. J Neurorestoratology, 2020, 8:197-216.
|
| 110 |
Huang H, Gao W, Yan Z, et al. Standards of clinical-grade olfactory ensheathing cell culture and quality control (2020 China Version)[J]. J Neurorestoratology, 2020, 8(4):217-231.
|
| 111 |
Cai M, Han F, Xiong N, et al. Standards of induced pluripotent stem cells derived clinical-grade neural stem cells preparation and quality control (2021 China version)[J]. J Neurorestoratology, 2021, 9(1):13-30.
|
| 112 |
Huang H, Raisman G, Sanberg PR, et al. Olfactory ensheathing cell in Neurorestoratology[M]. New York: Nova Biomedical, 2015: 68-71.
|
| 113 |
Huang H. Why is olfactory neuroepithelium?[J]. J Neurorestoratology, 2021, 9:211-218.
|